drugset / Trial / NCT06949852
Evaluation of Safety and Efficacy of Nalbuphine Versus Morphine for Postoperative Analgesia
Phase 3
Completed
289 enrolled
Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Evaluation of safety and efficacy of Nalbuphine versus Morphine patient controlled intravenous analgesia (PCIA) for the treatment of postoperative analgesia
Timeline
- Start
- 2024-08-07
- Primary completion
- 2025-07-08
- Completion
- 2025-08-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Morphine | Other / unclassified | — | Intravenous |
| Subject | Nalbuphine | Small molecule | — | Intravenous |
Indications
No indication recorded.